Anthropic IPO terms, valuation, and biotech IPO activity discussed
Summary
Hosts Abraham Marquez and Matt Kennedy analyze Anthropic's IPO structure, noting a $1.2 trillion midpoint valuation and a $61 billion primary raise targeting $100 billion total with greenshoe and private placement. They highlight Anthropic's $81 billion October revenue run rate, implying a ~15x multiple, and contrast its profitability with peers like OpenAI. The hosts discuss CEO Dario Amodei's narrative on $900 billion in compute commitments and concerns over customer acquisition costs via free tokens. Additional IPO activity includes Windward Bio's 68% first-day surge, Vivardis breaking issue, and American Barrick Gold's planned carve-out.
Key takeaways
- 1 Anthropic's IPO is 97% primary shares, meaning nearly all capital goes to the company for compute rather than early investor liquidity, with co-founders cashing out only ~$1.9 billion.
Matt Kennedy · 2:31
Episode sections
- 0:01 – 2:05
Podcast Intro and Market Overview
Hosts Abraham Marquez and Matt Kennedy introduce the week's IPO winner, Windward Bio, and loser, Vivardis. They highlight Anthropic's IPO terms as the main event, noting its $1.2 trillion midpoint valuation and the broader market context of AI infrastructure stocks rebounding.
- 2:05 – 3:33
Anthropic IPO Deal Structure and Sizing
Anthropic filed for 825 million shares at $70-$78, targeting a $61 billion raise at midpoint. The total potential raise could exceed $100 billion with the greenshoe and a $26 billion private placement. The stock will trade on NASDAQ under the symbol ANT.
- 3:33 – 5:15
Revenue Growth and Valuation Context
Anthropic reported $17 billion Q3 revenue with a $81 billion October run rate. At the midpoint, this implies a ~15x multiple on the run rate. Speakers compare this to OpenAI's reported valuation and revenue, noting Anthropic's profitability advantage.
- 5:15 – 7:10
Roadshow Narrative and Compute Commitments
CEO Dario Amodei emphasized underpromising and overdelivering, addressing the $900 billion in compute commitments as a potential capacity constraint rather than a burden. The company is expanding into pharma, cybersecurity, and end-user applications like a spreadsheet tool.
- 7:10 – 9:44
Revenue Quality and GPU Dependencies
Concerns remain about the cost of acquiring customers via free tokens, which are classified under compute rather than sales and marketing. The market's sensitivity to NVIDIA-related headlines (Jensen Huang) is noted as a volatility factor, though speakers view it as a fleeting headline risk.
- 9:44 – 11:45
Biotech and Other IPO Activity
Windward Bio surged 68% on day one, reinforcing biotech's strength. Vivardis broke issue due to high valuation. Rosera postponed its IPO. American Barrick Gold plans a carve-out raising over $5 billion in December, offering diversification from AI.
- 11:45 – 14:18
AI Infrastructure Read-Through and Market Leadership
Refreshers NScale, Aggreko, and Wella updated filings, betting on Anthropic reopening the window. AI infrastructure stocks, led by Fervo Energy, dominated gains, while Beta Technologies gave back previous gains. The IPO market's center of gravity is currently Anthropic.
- 14:18 – 16:54
Forward Outlook and Next Week's Events
Key focus is Anthropic's pricing on Wednesday and debut on Thursday. Speakers advise against reading too much into the first few hours of trading. Watch for NScale and Aggreko to launch if Anthropic succeeds, and Wella as a test for non-AI names.
Assets discussed
| Asset | Kind | Stance | Context |
|---|---|---|---|
| NVIDIANVDA | equity | neutral | Yes, general market volatility. Yes, NVIDIA is systematically important to the AI trade. And yes, it's a reminder of how wired this sector is to headlines right now. |
| Gold | commodity | neutral | And it's a nice contrast to everything else this week. Gold is about as far from the AI trade as you can get, which could make it appealing for investors looking to diversify. |
| Anthropic | private company | neutral | Granted, it's not an automatic plug. Um, a deal this big pulls a lot of capital and attention. And some investors may trim other AI positions to make room for their anthropic allocation. |
| S&P 500 | index | neutral | um but on to the scoreboard the IPO index rebounded 3.4% this week ahead of the SP 500's 2.5 percent gain |
“Stance” is how the speakers talked about the asset, not a recommendation.
Claims worth verifying
Windward Bio popped 68% in its first day of trading.
Unidentified speaker (UNKNOWN) ·0:01
How to verify: Check Windward Bio's first-day closing price vs. its IPO price in SEC filing or financial news archives. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceVivardis broke issue (traded below IPO price) despite a fast-growing story.
Unidentified speaker (UNKNOWN) ·0:01
How to verify: Check Vivardis's IPO price and first-day closing price in SEC filing or financial news archives. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceAnthropic's IPO midpoint valuation is $1.2 trillion.
Matt Kennedy ·0:12
How to verify: Verify against Anthropic's S-1 filing with the SEC EDGAR database. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceAnthropic plans to raise about $61 billion at the midpoint price.
Matt Kennedy ·0:12
How to verify: Calculate based on 825 million shares at $73.33 midpoint price in S-1 filing. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceAnthropic's October revenue run rate was $81 billion.
Matt Kennedy ·3:53
How to verify: Check the amended S-1 filing for the disclosed revenue run rate. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceOpenAI received a reported $1.25 trillion valuation with $10 billion quarterly revenue.
Matt Kennedy ·4:31
How to verify: Verify via reputable news sources reporting on OpenAI's latest funding round or valuation reports. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Windward Bio priced a full-size deal at the midpoint and soared 68% on day one.
Abraham Marquez ·9:44
How to verify: Check Windward Bio's pricing announcement and first-day trading data. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
American Barrick Gold could raise over $5 billion in December.
Unidentified speaker (UNKNOWN) ·11:06
How to verify: Check American Barrick Gold's prospectus or press releases regarding the carve-out. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
The IPO Index rebounded 3.4% this week, beating the S&P 500's 2.5% gain.
Abraham Marquez ·12:41
How to verify: Check Renaissance Capital's IPO Index performance data or major financial data providers for the week ending 2026-11-15. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Primary sourceFervo Energy rose 27.5%, leading AI infrastructure gains.
Unidentified speaker (UNKNOWN) ·12:49
How to verify: Check Fervo Energy's stock performance data for the week. For recent events, verify 2026-08-15 through 2026-11-15. Use another period only when the speaker explicitly names it.
Do your own research
- Verify Anthropic's S-1 filing for exact share counts, price range, and use of proceeds.
- Check SEC filings for Windward Bio's first-day trading volume and price action.
- Review American Barrick Gold's press release or SEC filing for the December carve-out details.
- Analyze Anthropic's revenue recognition policies to understand the classification of free token costs.
- Compare Anthropic's adjusted EBITDA margins to public AI infrastructure peers like NVIDIA or AMD.
- Monitor NVIDIA earnings calls or guidance for any updates on AI chip demand impacting Anthropic's compute commitments.
- Read CEO Dario Amodei's roadshow remarks or transcript for specific details on the $900 billion compute commitments.
- Check Vivardis's IPO pricing and first-day performance to assess market reception of high-valuation biotech names.
Full transcriptexpand
- 0:01
- Unidentified speaker (UNKNOWN): This
- 0:01
- Abraham Marquez: week's winner, Windward Bio, the asthma focused biotech that popped 68% in its first day of trading. This week's loser, Vivardis, which broke issue despite a fast-growing story.
- 0:12
- Matt Kennedy: But honestly, those are the opening acts. The headliner finally set its terms. Anthropic $1.2 trillion value at the midpoint, pricing Wednesday, trading on Thursday. And with the Ikeo IPO index bouncing back and AI headlines whipping the sector around. the real question is whether one deal can swing the window back open for everyone waiting behind it. Let's get into
- 0:32
- Matt Kennedy: it with this week's Winner and Losers.
- 0:38
- Unidentified speaker (UNKNOWN): Welcome
- 0:39
- Abraham Marquez: to the IPO Winners and Losers Podcast. I'm your host, Abraham Marquez, Renaissance Capital's Director of Investment Strategies.
- 0:45
- Unidentified speaker (UNKNOWN): And
- 0:45
- Matt Kennedy: I'm Matt Kennedy, Senior Strategist at Renaissance Capital.
- 0:49
- Abraham Marquez: Quick note before we dive in this podcast. is for informational purposes only, and nothing we discuss should be taken as investment advice or a recommendation to buy, sell, or hold any security. Past performance does not guarantee future results, and one cannot invest directly in an index. For the full disclosure, check the end of this recording.
- 1:05
- Unidentified speaker (UNKNOWN): So
- 1:05
- Abraham Marquez: let's walk through the week because after a long stretch of guessing, we finally have actual deal terms to talk about. We did the will they won't they routine on Anthropic for months.
- 1:15
- Abraham Marquez: Half of that was over when it submitted the initial filing. And now we have the rest. Range, deal size, valuation, dates. It's all on the table.
- 1:23
- Unidentified speaker (UNKNOWN): Yeah,
- 1:23
- Matt Kennedy: and you could see the market rearranging itself around that date. Only one new filing this week, but a handful of companies refreshed their paperwork with Q3 numbers. So now No, they're lining up behind the big one.
- 1:35
- Abraham Marquez: The actual deal flow was pretty light though. Um, all in health. healthcare, two pricings, and notably one postponement. Biotech has shown that it's still the most reliable buyer base out there, but this week showed it's not a free pass.
- 1:48
- Unidentified speaker (UNKNOWN): And
- 1:48
- Matt Kennedy: the tape cooperated, which matters going into a deal this size. IPO index up three point four percent, beating the SP five hundred, with AI infrastructure Structure doing the heavy lifting there. I would say that they couldn't have asked for a better week to file, but well. I guess we'll get into that later.
- 2:05
- Abraham Marquez: Yes, we will. But that's a rotation we haven't seen in a while. Um, now let's go to the headline. Anthropics terms, because the structure says a lot on its own. Here's the setup: $825 million shares at a range of $70 to $78. At the midpoint, that's a $61 billion raise at a $1.2 trillion market cap. Pricing
- 2:25
- Abraham Marquez: Wednesday the 18th, trading $33. Thursday the 19th on the NASDAQ under the symbol ant, A-N-T.
- 2:31
- Unidentified speaker (UNKNOWN): Uh
- 2:31
- Matt Kennedy: first I'll highlight that this is a 97% primary share offering. This isn't early investors heading for the exits by any means. The co-founders are only cashing out about uh $1.9 billion, a mere $1.9B. So almost every dollar goes to the company, and we all know where most of that's headed. Compute.
- 2:50
- Unidentified speaker (UNKNOWN): Mm-hmm. I
- 2:51
- Abraham Marquez: know that was something that caught my eye in the blank filing, wondering how much of this was going to be a liquidity event rather than a true raise. Um, but back to that size, sixty-one billion dollars actually understates the total, assuming pricing at the top, full exercise of the green shoe, plus that twenty six billion dollar private placement, and you're potentially north of a hundred billion
- 3:11
- Abraham Marquez: dollars raised.
- 3:12
- Unidentified speaker (UNKNOWN): Yeah,
- 3:12
- Matt Kennedy: that that private placement does take some of the pressure. off of the public tranch, uh, unless people start worrying about AI circular spending again. But hey, $26 billion is $26 billion.
- 3:23
- Unidentified speaker (UNKNOWN): Plus
- 3:23
- Abraham Marquez: the newsletter makes the point that on deals this big, bankers usually leave themselves room above the midpoint. So I guess think of the range as an opening bid rather than a forecast.
- 3:33
- Matt Kennedy: I was surprised. It seemed lower than I thought that would go. Um so that's actually a pretty good thing for IPO buyers. Uh but uh first a quick refresher on some of the numbers here. $17 billion of revenue in Q3 with a 15% adjusted EBITDA margin. Annualized that quarter, and you've got about $68 billion for revenue. Uh
- 3:53
- Matt Kennedy: however, the October run rate that was disclosed in the amended S1 was revealed to be $81 billion. That's a meaningful step up in just a few weeks.
- 4:01
- Unidentified speaker (UNKNOWN): Yeah,
- 4:01
- Abraham Marquez: which puts the midpoint. at roughly 15 times that run rate. I won't be the first or the only one to say it. That's not cheap. You're paying for the curve to keep bending upward.
- 4:11
- Matt Kennedy: Yeah, I mean not cheap in the traditional sense, uh certainly not on trailing figures. But if you are willing to look at 2028, it could be cheap. Um, I think you, you know, you have to comp it against the cream of the crop here. You're looking at Palantir's Palantir, Snowflake, SpaceX. A positive adjusted EPITA at this growth rate
- 4:31
- Matt Kennedy: is something that a lot of AI companies can't even show you at all. So yes, it's a premium, but at least there's something underneath it. And uh, you know, you can just look at OpenAI this week. Uh getting a reported one point two five trillion dollar valuation with ten 10 billion in quarterly revenue, net of partner fees, with a negative one 100% hundred percent adjustment. adjusted operating
- 4:51
- Matt Kennedy: loss. That's that's practically the same proposed value as anthropic, but at a far lower revenue base and uh far steeper losses.
- 5:02
- Abraham Marquez: Kind of makes sense now why we're seeing anthropic now and maybe not OpenAI, although uh we'll see what happens in 2027, um, and if they can, yeah, get the numbers up to maybe where investors are now expecting them to be.
- 5:15
- Unidentified speaker (UNKNOWN): Um,
- 5:16
- Abraham Marquez: and this all kind of ties into what management is actually telling investors on the road. Uh co-founder and CEO, Dario Amode, is out on the roadshow, plus a fireside chat with Jamie Diamond, and he repeated the promise that the company will underpromise and overdeliver for shareholders.
- 5:32
- Matt Kennedy: Best not to think about that one too hard. That's my favorite f favorite line from the newsletter, repeatedly saying that he aims to underpromise and overdeliver. That's just too funny.
- 5:41
- Abraham Marquez: And I guess to his credit, he went straight at the big investor concerns. I feel like that's kind of a low bar. Um, but this is a marketing push after all, so he could have skirted those issues. Um, the biggest issue obviously being that $900 billion in compute commitments. Um, his argument is that it actually might fall short of demand.
- 5:59
- Unidentified speaker (UNKNOWN): Yeah,
- 6:00
- Matt Kennedy: that's the claim at least that he he tried to make. Um probably the boldest claim on that video, which is linked to in the newsletter. Bears will probably look at that $900 billion against an $81 billion run rate and see a massive obligation. Uh, he's reframing it as a possible capacity constraint. Either way, if you buy this
- 6:20
- Matt Kennedy: stock, you're really underwriting AI demand broadly, uh, not just one company.
- 6:24
- Abraham Marquez: Then on the low low-cost cost competitors, he pointed to Haiku as the answer. And on growth, he flagged pharma and cybersecurity. Plus, the company launched its own spreadsheet tool this week. So it's clearly pushing further into that kind of end user application layer. I'm a pretty diehard Excel fan, so I'm a little skeptical, but generally I've seen positive feedback.
- 6:43
- Matt Kennedy: Yeah, going after Excel, So that is a uh a tough nut to crack. But hey, they are taking a lot of big swings. Take enough big swings and you'll crack some nuts. Maybe you'll
- 6:51
- Unidentified speaker (UNKNOWN): even
- 6:51
- Matt Kennedy: get a grand slam or a hole in one.
- 6:53
- Unidentified speaker (UNKNOWN): Lot
- 6:54
- Abraham Marquez: of sports references there.
- 6:56
- Matt Kennedy: But the hardest data point wasn't on stage. It was in the filing. As we were talking about earlier, that $81 billion October run rate, up 10 billion from September, probably uh calmed some investors worried about growth slowing in Q3.
- 7:10
- Unidentified speaker (UNKNOWN): I
- 7:10
- Abraham Marquez: think the biggest pushback though is that we don't know really what it costs to get there. Um, sales and marketing spend behind that run rate is still a bit of a black box. The newsletter joked that our IT team appreciates all the free tokens, but free tokens are customer acquisition cost.
- 7:25
- Unidentified speaker (UNKNOWN): Uh
- 7:25
- Matt Kennedy: agreed. Yeah, uh quality of revenue is the question with any hyper-growth IPO, and this one's no exception. I'd want to see that spend line in the first couple of earnings reports. And it's kind of tricky actually with this one because uh free tokens. actually get put in the compute bucket rather than the main SM one. So something to
- 7:43
- Unidentified speaker (UNKNOWN): keep
- 7:43
- Matt Kennedy: in mind.
- 7:44
- Abraham Marquez: Yeah. And then there's the 800 pound GPU in the room, the turmoil around Jensen Huang. The newsletter is inclined to look past it.
- 7:53
- Matt Kennedy: Of course, I am under no such obligation. Avery, can you believe what happened this week? Such high quality memes.
- 7:59
- Unidentified speaker (UNKNOWN): Of
- 7:59
- Matt Kennedy: course, in the context of anthropic, I'm I'm not gonna say going that. to there's no there there, but it is sort of hard to make a direct connect connection to the IPO. Yes, general market volatility. Yes, NVIDIA is systematically important to the AI trade. And yes, it's a reminder of how wired this sector is to headlines right now. Expectations are
- 8:19
- Matt Kennedy: so high that almost any story can move AI stocks sharply in either direction. But it is also easy to over-emphasize. the connection. You know, it's it's a fleeting headline. It's uh you know ripped from the headlines, it's got everyone's attention, but that will fade. This IPO is a landmark moment for capital markets, regardless.
- 8:39
- Matt Kennedy: But yeah, I mean, Bet uh Bet Anthropic didn't have that on their bingo cards. I mean, it is hard to imagine any story overshadowing Anthropic, but uh hey, Jensen Huang's a fan. affairs. Anyway, I'm I don't know. Moving on, moving on. Unless you want to talk about it. No,
- 8:57
- Abraham Marquez: I'll just say that I think
- 9:00
- Abraham Marquez: the more golden the guy, the harder the fall, I guess.
- 9:05
- Unidentified speaker (UNKNOWN): Yeah.
- 9:06
- Matt Kennedy: Yeah.
- 9:06
- Abraham Marquez: Gensanity is over. So
- 9:09
- Unidentified speaker (UNKNOWN): I mean,
- 9:09
- Matt Kennedy: you think
- 9:10
- Unidentified speaker (UNKNOWN): he'll
- 9:10
- Matt Kennedy: have a second act?
- 9:12
- Unidentified speaker (UNKNOWN): I
- 9:12
- Abraham Marquez: don't know. This is a pretty I think the affairs could maybe be overlooked, but it's the whole spy angle. I th I I would say that's more what markets are at that like this is going to be
- 9:26
- Unidentified speaker (UNKNOWN): I
- 9:27
- Abraham Marquez: don't know. This is gonna play out I feel like over a longer period of time than than maybe some people might anticipate.
- 9:34
- Matt Kennedy: I I was I was wincing a lot, I was going and I was going, ooh, a lot of ooh and a lot of
- 9:39
- Matt Kennedy: you know.
- 9:40
- Unidentified speaker (UNKNOWN): Yeah,
- 9:41
- Abraham Marquez: well, what other reaction can you have?
- 9:44
- Abraham Marquez: Um, but onto the deal side. And Frogpick wasn't the only one with a big week. Uh Winward Bio, which is a biotech targeting asthma, priced a full size deal at the midpoint and soared 68% on day one. Um, so that really keeps biotech's hot streak going.
- 9:59
- Unidentified speaker (UNKNOWN): Yeah,
- 9:59
- Matt Kennedy: at this point, biotech seems like the most dependable bid in the market for. a while. A pop like that tells you that investors still want biotech stories with a clear target market.
- 10:08
- Unidentified speaker (UNKNOWN): Mm-hmm.
- 10:09
- Abraham Marquez: Then Vivardis, the fast growing cavity treatment provider. This one was a little weird cutting the shares before pricing and then offering more, but pricing below the range. Um, but at any rate, it broke issue. Looking at our model, it did look expensive. So good company, but pretty pricey.
- 10:25
- Unidentified speaker (UNKNOWN): Yeah,
- 10:26
- Matt Kennedy: that's uh a useful reminder that fast growing doesn't necessarily guarantee a pop, and it's a different kind of healthcare story than a, you know, say clinical stage biotech. So I wouldn't read that as a crack in the sector bid.
- 10:38
- Abraham Marquez: Mm-hmm. But then you have Rosera, which postponed. Um, and the newsletter's framing here is that biotechs really just aren't getting a blank check.
- 10:47
- Matt Kennedy: That's healthy, frankly. A market that takes everything is a market that is about to get burned. So selectivity is what keeps a hot streak alive.
- 10:54
- Abraham Marquez: Mm-hmm. And that kind of brings us to who's lining up behind Anthropic. We had only one filing this week, but it's a big one. American Barrick Gold, which could raise over $5 billion in December.
- 11:06
- Unidentified speaker (UNKNOWN): So
- 11:06
- Matt Kennedy: this is parent barrack mining carving out its gold assets as a pure play, betting that the standalone company gets a better valuation than it does inside the bigger. company. So classic unlock the value move here.
- 11:18
- Abraham Marquez: And it's a nice contrast to everything else this week. Gold is about as far from the AI trade as you can get, which could make it appealing for investors looking to diversify.
- 11:27
- Unidentified speaker (UNKNOWN): The
- 11:27
- Matt Kennedy: the timing is a bit aggressive. Uh I will say that. December calendars usually thin out as the holidays get close. So a five plus billion dollar deal in that window shows some real confidence.
- 11:38
- Abraham Marquez: Mm-hmm. I guess they're hoping for a Santa rally. Uh maybe jewelry. I don't know.
- 11:43
- Unidentified speaker (UNKNOWN): Aren't
- 11:43
- Matt Kennedy: we all?
- 11:45
- Abraham Marquez: Um and then we had the refreshers, uh, NScale, the NeoCloud, Agreco, Power Equipment, and Wella, the beauty brand owner. Um, all of them updated with Q3 numbers. Essentially, betting anthropic can reopen the window.
- 11:57
- Unidentified speaker (UNKNOWN): Yeah,
- 11:57
- Matt Kennedy: two of those are related to AI infrastructure. So the read-through read through is pretty direct. NScale, N scale, especially, I mean, a strong anthropic. debut here is basically the best marketing a compute provider could ask for.
- 12:07
- Abraham Marquez: Granted, it's not an automatic plug. Um, a deal this big pulls a lot of capital and attention. And some investors may trim other AI positions to make room for their anthropic allocation.
- 12:18
- Matt Kennedy: That's fair. And it's a real near term risk. Uh but if anthropic does trade well, it gives every AI name behind it a fresh comp and a confidence boost so you know I take that trade off
- 12:29
- Abraham Marquez: yeah
- 12:30
- Unidentified speaker (UNKNOWN): and
- 12:30
- Matt Kennedy: and anthropic's gonna raise a ton of money and they can use that money on n scale
- 12:35
- Abraham Marquez: yeah oh and circular spending that's yeah we can just forget that right
- 12:41
- Abraham Marquez: um but on to the scoreboard the IPO index rebounded 3.4% this week ahead of the SP 500's 2.5 percent gain
- 12:49
- Unidentified speaker (UNKNOWN): yeah
- 12:49
- Matt Kennedy: and the the leadership is telling AI infrastructure dominated the winners, led by Fervo Energy, the next gen geothermal producer, up 27.5%.
- 12:58
- Unidentified speaker (UNKNOWN): Yeah,
- 12:58
- Abraham Marquez: Fervo had a pretty tough break through October. So good to see it on the winners list this week. Um, power is increasingly the bottleneck in the AI build out. We've seen that. Um, and the market is paying for it.
- 13:08
- Unidentified speaker (UNKNOWN): On the
- 13:08
- Matt Kennedy: flip side, last week's winner is this week's loser. Uh, beta technologies, the electric aircraft maker, gave back 14.
- 13:16
- Unidentified speaker (UNKNOWN): Yeah,
- 13:16
- Abraham Marquez: that's the whiplash in this market right now. Leadership flips week to week. And sometimes momentum names give it back just as fast as they make it.
- 13:24
- Matt Kennedy: Mm-hmm.
- 13:25
- Unidentified speaker (UNKNOWN): So
- 13:25
- Abraham Marquez: stepping back, what does a week like this really tell us? The IPO market has a single center of gravity right now. Everything, the refreshers, the December gold deal, even how people talk about biotech is being measured against anthropic.
- 13:38
- Unidentified speaker (UNKNOWN): And if
- 13:39
- Matt Kennedy: it clears well, it's a statement that public markets can fund AI at the scale private markets have been funding it. That's the seminal part. It's not just a big listing, it's a new kind of public company.
- 13:49
- Abraham Marquez: Mm-hmm.
- 13:49
- Unidentified speaker (UNKNOWN): And the
- 13:50
- Abraham Marquez: flip side there is the concentration risk. If anthropic stumbles, it doesn't only hit one stock, it hits NScale, Greco, the whole AI infrastructure group that's waiting on it.
- 13:59
- Matt Kennedy: Agreed, which is why the rest of the week matters. Biotech is still pricing, a gold carve out is coming, a beauty brand is warming up. The calendar isn't all just one big bet.
- 14:09
- Unidentified speaker (UNKNOWN): And
- 14:10
- Abraham Marquez: then the tape gave issuers what they needed. The question now is whether investors bring the same appetite to a deal with a trillion dollar price tag.
- 14:18
- Unidentified speaker (UNKNOWN): All
- 14:19
- Abraham Marquez: right. So what are we watching next week? Obviously, anthropic pricing on Wednesday, where the price lands relative to the range, whether they upsize that's going to be one clue about how deep the book really is.
- 14:30
- Matt Kennedy: And then the actual debut on Thursday, uh, I'd caution against reading too much into the first few hours. How it trades in the following days is the better signal. I mean, the IPO is just one day. So
- 14:42
- Abraham Marquez: stay
- 14:42
- Matt Kennedy: tuned.
- 14:43
- Abraham Marquez: Yeah.
- 14:43
- Unidentified speaker (UNKNOWN): Um,
- 14:44
- Abraham Marquez: and then whether any of the refreshers launch right after it. Uh and scale and a agreco greco are the ones I'd watch for an AI read through. Um but Wella uh could be the tell of whether non-AI AI names will follow.
- 14:56
- Unidentified speaker (UNKNOWN): Yeah,
- 14:56
- Matt Kennedy: and then we're also looking just, you know, AI headlines in general. I guess we never know what we can expect in a market like this.
- 15:03
- Unidentified speaker (UNKNOWN): But
- 15:03
- Matt Kennedy: with expectations this high, any news on the sector's biggest names can move the tape and the pricing.
- 15:10
- Abraham Marquez: Months of waiting. I cannot emphasize that enough.
- 15:13
- Unidentified speaker (UNKNOWN): Yeah.
- 15:13
- Abraham Marquez: Um, and now one week to find
- 15:14
- Unidentified speaker (UNKNOWN): out. out. And
- 15:16
- Matt Kennedy: that's it for this week's winners and losers. Get the full newsletter in your inbox by clicking the link in the description.
- 15:22
- Abraham Marquez: However, you choose to tune in, please like and subscribe or rate and download. It helps us reach more people who might be interested in the wonderful world of IPOs.
- 15:31
- Matt Kennedy: Thanks for listening. And before we go, Avery, should we plug the uh Bill interview that we had this week?
- 15:37
- Abraham Marquez: Oh yeah.
- 15:38
- Unidentified speaker (UNKNOWN): If you haven't seen
- 15:39
- Matt Kennedy: it, people, we did an interview with our CEO, Bill Smith.
- 15:44
- Unidentified speaker (UNKNOWN): Yeah,
- 15:45
- Abraham Marquez: talking about uh well, yeah, talking about uh the AI trade, um his new book, The New AI Stock Edge. Um and it was I think a really you know insightful episode. Um
- 15:55
- Abraham Marquez: as somebody who works in this field, I think I learned a lot from somebody who's worked in this field like I don't know, five times longer than I. have.
- 16:03
- Matt Kennedy: Yeah. Um, and it always it already seems like uh this new book is getting a lot of excitement. So we're all we're all joining in that excitement uh with the uh I think early December launch of that one. So uh
- 16:16
- Unidentified speaker (UNKNOWN): yeah,
- 16:16
- Matt Kennedy: getting back to the your favorite part, the disclosures here. This podcast is for informational purposes only. Renaissance capital savings statements should not be considered investment advice or recommendation to buy, sell or hold. any particular security. Certain of the statements contained maybe statements of future expectations and other forward-looking statements that are based on Renaissance Capital's current views and assumptions and involve known and unknown risks
- 16:36
- Matt Kennedy: and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied by such statements. Past performance does not guarantee future results. One cannot invest directly in an index.